<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216980</url>
  </required_header>
  <id_info>
    <org_study_id>HM20009929</org_study_id>
    <nct_id>NCT03216980</nct_id>
  </id_info>
  <brief_title>Examining the Effect of Mental Health Disorders on Vascular Function and Exercise Tolerance</brief_title>
  <official_title>Examining the Effect of Mental Health Disorders on Vascular Function and Exercise Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim #1: Examining the impact of mental health disorders (PTSD and GAD) on peripheral
      vascular function and sympathetic nervous system activity in young individuals.

      Specific Aim #2: Examining the impact of mental health disorders (PTSD and GAD) on peripheral
      hemodynamics and metabolic byproducts during small muscle mass exercise in young individuals.

      Specific Aim #3: Examining the impact of mental health disorders (PTSD and GAD) on exercise
      tolerance, peripheral hemodynamics and metabolic byproducts during large muscle mass exercise
      in young individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mental health disorders are highly prevalent and underdiagnosed and can cause perturbations
      in cardiovascular and metabolic function leading to substantial individual burden (increased
      health care cost, loss of work productivity). Post-traumatic stress disorder (PTSD) and
      generalized anxiety disorder (GAD), two common mental health disorders, can cause increase
      cardiovascular disease risk due to chronic increases or fluctuations in heart rate, blood
      pressure, stress hormones, inflammation, and oxidative stress. Post-traumatic stress disorder
      (PTSD) is a disabling psychiatric condition characterized by a persistent maladaptive
      reaction resulting from exposure to severe psychological stress. It has been revealed that
      individuals with PTSD, in addition to adverse mental health symptoms, also possess higher
      prevalence rates for physical comorbidities such as hypertension, obesity, diabetes, and
      metabolic syndrome. Taken together, these PTSD-induced comorbidities result in a significant
      increase in the likelihood of developing cardiovascular disease (CVD) when compared to
      individuals without PTSD. Anxiety disorders, the most prevalent mental health issue in the
      United States, is associated an increased incidence of hypertension and heart disease. This
      increased cardiovascular disease (CVD) risk is thought to derive from an overactivation of
      the sympathetic nervous system that results in a predominately pro-oxidant, pro-inflammatory
      cardiovascular environment. Peripheral vascular dysfunction, or the inability of the blood
      vessels to adequately respond to specific stimuli, is a factor closely related to CVD.
      Therefore, this study will focus on a younger population with PTSD or GAD in an attempt to
      ascertain the presence of peripheral vascular dysfunction and the magnitude to which two
      potential primary contributors (autonomic dysfunction, oxidative stress) are involved in this
      dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm Vascular Function at Rest (Flow Mediated Dilation Test) and in Response to Exercise (Handgrip Exercise Test)</measure>
    <time_frame>Before and Immediately After Intervention</time_frame>
    <description>Change in Brachial Artery Dilation from Baseline Values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg Vascular Function (Passive Leg Movement Test)</measure>
    <time_frame>Before and Immediately After Intervention</time_frame>
    <description>Change in Leg Blood Flow Values from Baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Mental Health Disorders</condition>
  <arm_group>
    <arm_group_label>PTSD/GAD Antioxidant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTSD/GAD Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PTSD/GAD Antioxidant</intervention_name>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
    <arm_group_label>PTSD/GAD Antioxidant</arm_group_label>
    <arm_group_label>PTSD/GAD Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PTSD/GAD Placebo</intervention_name>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
    <arm_group_label>PTSD/GAD Antioxidant</arm_group_label>
    <arm_group_label>PTSD/GAD Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Healthy Control Antioxidant</intervention_name>
    <description>Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).</description>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Healthy Control Placebo</intervention_name>
    <description>Subjects will ingest placebo (microcrystalline cellulose) pills.</description>
    <arm_group_label>Healthy Control Antioxidant</arm_group_label>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  apparently healthy and free of overt cardiovascular, pulmonary, or metabolic disease

          -  for PTSD group, a score of ≥ 33 on PCL-5 checklist

          -  for GAD group, a score of ≥ 10 on the GAD-7 self-report scale

        Exclusion Criteria:

          -  taking medications that could influence cardiovascular function

          -  limited English proficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Garten, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>vascular function</keyword>
  <keyword>PTSD</keyword>
  <keyword>GAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

